Corneal Nerves Function and Structure
Key facts
- Who runs it
- VA Office of Research and Development
- Where
- Iowa City, United StatesSee the site
- Trial code
- Status
- Completed
- People taking part
- 44 people enrolled
- Started
- 21 Jun 2021
- Ended
- 13 May 2025
- Type of study
- Interventional, 3 groups
- Treatments tested
- Blackmores Omega Daily (4 1g capsules per day)
- Record updated
- 23 May 2025
Who can take part
- Age
- 50 years to 75 years
- Sex
- Women and men
- Healthy volunteers
- Can take part
Show the full registry criteria (17)Hide the full registry criteria
Who can take part
- Type 2 diabetes patients diagnosed based on the opinion of an Endocrinologist (Dr. Correia), the absence of a history of ketoacidosis, and a C-peptide > 0.8 ng/ml
- At least 5 year known duration of diabetes
- HbA1c < 9.0%
- None or mild to moderate peripheral neuropathy based on medical record, Michigan Neuropathy Screening Instrument including response to monofilament test, ankle reflex test, vibration perception threshold examination using a 128 Hz tuning fork as well as hot and cold sensation evaluation
Who cannot take part
- Any neurologic, muscular, genetic, or other condition known to affect nerve or muscle function
- Peripheral vascular, cardiac, pulmonary, or any other disorder affecting blood or tissue oxygenation
- Risk of bleeding disorder or on medication known to increase risk of bleeding
- Any other medical or psychological condition judged to limit compliance with the protocol or interpretation of results
- History of diabetic foot ulcer
- Insulin use to manage diabetes 200 units
- History of taking fish oil supplements
- Electrolyte abnormalities, untreated hypothyroidism, abnormalities in calcium, phosphate, or magnesium concentrations, or any other metabolic disturbance affecting neural function
- Cigarette smoking in the past year
- History for use of aspirin
- LDL > 100 mg/100ml, HDL < 30 mg/100ml, Triglyceride > 400 mg/100ml.* 10) BP < 140 systolic and 80 diastolic
- BMI 45
- The investigators are limiting subject population to those over 50 thus pregnancy should not be an issue nonetheless females who are pregnant, looking to become pregnant or are breast feeding will be excluded (* After overnight fast of 8-12 h; Average of three determinations in the sitting position after at least 5 minutes rest.)
Where in United States
- Iowa City VA Health Care System, Iowa City, IAIowa City, United States
About the trial
What the trial wants to find out
Peripheral neuropathy affects about 50% of the diabetic population and there is no treatment other than good blood glucose control, which is ineffective in subjects with type 2 diabetes. Part of the problem for the lack of an effective treatment is the inability to detect peripheral neuropathy in its early stage. The hypotheses to be addressed in the first phase of this study is that changes in cornea sensitivity (blinking and squinting) following addition of a hyperosmotic solution will provide a novel screening tool for early diagnosis of peripheral neuropathy. For the second phase of the study the investigators will examine the effect of fish oil treatment of diabetic subjects with neuropathy on corneal nerve density and sensitivity. Corneal nerves are the most highly innervated part of the human body with great sensitivity. The first phase will use this property and determine whether sensitivity is lost in diabetic patients with neuropathy. Preclinical studies have supported this hypothesis and now this will be tested in human subjects. Preclinical studies have also shown that treating diabetic rodents with fish oil improves nerve regeneration and outcome measures of peripheral in diabetic rodents. In the second phase the investigators will perform preliminary studies in human subjects with diabetic neuropathy and determine whether treating them with fish oil increases corneal nerve density and sensitivity.
The 3 groups in the trial
- Type 2 diabetes without neuropathyTreatment being tested
Subjects with type 2 diabetes will be enrolled and determination if they have neuropathy will be determined from their clinical record and evaluation.
Treatment: Blackmores Omega Daily (4 1g capsules per day)
- Type 2 diabetes with neuropathyTreatment being tested
Subjects with type 2 diabetes will be enrolled and determination if they have neuropathy will be determined from their clinical record and evaluation.
Treatment: Blackmores Omega Daily (4 1g capsules per day)
- Normal subjects, aged match with no symptoms of diabetesTreatment being tested
Healthy, aged matched control subjects will be enrolled and determination if they have neuropathy will be determined from their clinical record and evaluation.
Treatment: Blackmores Omega Daily (4 1g capsules per day)
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Diabetic Neuropathy: Function-Structure of Corneal Nerves to Assess Injury-Repair
- Record updated
- 23 May 2025